Filter by Event: IDWeek 2026
Activity of Omadacycline and Comparators Against Common Microbial Contaminants: Cronobacter sakazakii, Pluralibacter gergoviae, and Burkholderia cepacia species complex Isolates
Activity of Omadacycline and Comparators Against Common Microbial Contaminants: Cronobacter sakazakii, Pluralibacter gergoviae, and Burkholderia cepacia species complex Isolates. Lead author: Michael D. Huband, presented at IDWeek 2026, Oct 24, Washington D.C., USA
Poster P-488
In Vitro Activity of Omadacycline against 7,200 Bacterial Clinical Isolates Representing Multiple Infection Types from the United States (2024–2025)
In Vitro Activity of Omadacycline against 7,200 Bacterial Clinical Isolates Representing Multiple Infection Types from the United States (2024–2025). Lead author: Michael D. Huband, presented at IDWeek 2026, Oct 24, Washington D.C., USA
Poster P-383
Antimicrobial Susceptibility and Molecular Characterization of Carbapenem-Resistant Klebsiella pneumoniae from United States Medical Centers (2020–2025)
Antimicrobial Susceptibility and Molecular Characterization of Carbapenem-Resistant Klebsiella pneumoniae from United States Medical Centers (2020–2025). Lead author: Helio S. Sader, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-75
Aztreonam-avibactam activity against Enterobacterales from United States medical centers: Summary of 5 years of surveillance prior to approval for clinical use (2020–2024)
Aztreonam-avibactam activity against Enterobacterales from United States medical centers: Summary of 5 years of surveillance prior to approval for clinical use (2020–2024). Lead author: Helio S. Sader, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-117
Reproducibility of Cefiderocol-Xeruborbactam in Cation Adjusted Mueller Hinton Broth (CAMHB) and Iron Depleted (ID) CAMHB Using Two Reading Endpoints
Reproducibility of Cefiderocol-Xeruborbactam in Cation Adjusted Mueller Hinton Broth (CAMHB) and Iron Depleted (ID) CAMHB Using Two Reading Endpoints. Lead author: Mariana Castanheira, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-172
Activity of Cefiderocol-Xeruborbactam and Comparator Agents against Pseudomonas aeruginosa, Including Molecularly Characterized Isolates Recovered Globally in 2024
Activity of Cefiderocol-Xeruborbactam and Comparator Agents against Pseudomonas aeruginosa, Including Molecularly Characterized Isolates Recovered Globally in 2024. Lead author: KM Papp-Wallace, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-168
Activity of manogepix against mold isolates across geographic regions
Activity of manogepix against mold isolates across geographic regions. Lead author: Marisa L Winkler, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-18
Antimicrobial Susceptibility of KPC-Producing Enterobacterales and Molecular Characterization of Ceftazidime-Avibactam-Resistant Strains from United States Medical Centers (2018–2025)
Antimicrobial Susceptibility of KPC-Producing Enterobacterales and Molecular Characterization of Ceftazidime-Avibactam-Resistant Strains from United States Medical Centers (2018–2025). Lead author: Helio S. Sader, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-116
Activity of manogepix against Aspergillus spp. isolates with CYP51 alterations
Activity of manogepix against Aspergillus spp. isolates with CYP51 alterations. Lead author: Marisa L Winkler, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-17
Activity of IV fosfomycin against Enterobacterales collected from US medical centers during 2020–2023
Activity of IV fosfomycin against Enterobacterales collected from US medical centers during 2020–2023. Lead author: KM Papp-Wallace, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-169
In vitro Activity of Cefiderocol Against a Collection of Infrequently Isolated Gram-Negative Bacterial Isolates from the SENTRY Antimicrobial Surveillance Program
In vitro Activity of Cefiderocol Against a Collection of Infrequently Isolated Gram-Negative Bacterial Isolates from the SENTRY Antimicrobial Surveillance Program. Lead author: Joshua M. Maher, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-141
Antimicrobial Activity of Aztreonam-Avibactam against Enterobacterales Isolated from Patients with Ventilator-Associated Pneumonia (VAP)
Antimicrobial Activity of Aztreonam-Avibactam against Enterobacterales Isolated from Patients with Ventilator-Associated Pneumonia (VAP). Lead author: Mariana Castanheira, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-132
Activity of manogepix against yeast and mold isolates from 2025 in the United States
Activity of manogepix against yeast and mold isolates from 2025 in the United States. Lead author: Marisa L Winkler, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-19
Aztreonam-Avibactam Activity against Gram-negative Bacteria Isolated from Patients Hospitalized with Pneumonia in United States Medical Centers (2023–2025)
Aztreonam-Avibactam Activity against Gram-negative Bacteria Isolated from Patients Hospitalized with Pneumonia in United States Medical Centers (2023–2025). Lead author: Helio S. Sader, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-118
Activity of rezafungin against Aspergillus spp. that are non-wild-type to azole antifungal agents
Activity of rezafungin against Aspergillus spp. that are non-wild-type to azole antifungal agents. Lead author: Marisa L Winkler, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-20
Activity of cefiderocol-xeruborbactam and comparator agents against global Acinetobacter baumannii-calcoaceticus species complex isolates
Activity of cefiderocol-xeruborbactam and comparator agents against global Acinetobacter baumannii-calcoaceticus species complex isolates. Lead author: John H. Kimbrough, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-167
Activity of Ceftazidime-Avibactam against Pseudomonas aeruginosa from Patients with Ventilator-Associated Pneumonia (VAP) from United States Medical Centers (2021–2025)
Activity of Ceftazidime-Avibactam against Pseudomonas aeruginosa from Patients with Ventilator-Associated Pneumonia (VAP) from United States Medical Centers (2021–2025). Lead author: Helio S. Sader, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-115
In Vitro Activity of Ceftobiprole and Comparator Agents Against Contemporary U.S. Clinical Isolates Collected in 2025 Following FDA Approval
In Vitro Activity of Ceftobiprole and Comparator Agents Against Contemporary U.S. Clinical Isolates Collected in 2025 Following FDA Approval. Lead author: Rodrigo E. Mendes, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-142
Activity of Cefiderocol-Xeruborbactam and Comparator Agents against Enterobacterales, Including Molecularly Characterized Isolates Recovered Globally in 2024
Activity of Cefiderocol-Xeruborbactam and Comparator Agents against Enterobacterales, Including Molecularly Characterized Isolates Recovered Globally in 2024. Lead author: KM Papp-Wallace, presented at IDWeek 2026, Oct 22, Washington D.C., USA
Poster P-166
